Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Obesity (Silver Spring). 2021 Jul;29(7):1215–1222. doi: 10.1002/oby.23181

Figure 2. Change in weight by deciles of change in NT-proBNP over the 6-year follow up period (A) and after exclusion of participants with heart failure occurring at or prior to visit 4 (B), the Atherosclerosis Risk in Communities (ARIC) Study (1990-1992 to 1996-1998).

Figure 2.

Figure 2.

(A) and (B) are adjusted for age, sex, race-center, smoking status, estimated glomerular filtration rate, hypertension, diabetes, heart failure, atherosclerotic cardiovascular disease (coronary heart disease or stroke), total cholesterol, high-density lipoprotein-cholesterol and lipid lowering medication. Statistically significant decreases in weight were observed when NT-proBNP levels increased by more than 59.1 pg/mL (A) and 54.8 pg/mL (B) in the 6-year follow up. Decreases in NT-proBNP levels of more than 22.3 pg/mL over the same period were associated with statistically significant increases in weight (A).